AHS Cancer Control Alberta
albertahealthservices.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
186
Active
37
Phase 3
9
Total enrollment
27,034
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ferric derisomaltose | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | 2 | ||
| Temozolomide | — | — | — | — | 2 | ||
| Levothyroxine Oral Tablet [Synthroid] | — | — | — | — | — | 1 | |
| [177]Lu-DOTA-TATE | — | — | — | — | — | 1 | |
| [68]Ga-HA-DOTATATE | — | — | — | — | — | 1 | |
| nab-paclitaxel in combination with gemcitabine + cisplatin | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Chemo-Radiotherapy with concurrent temozolomide. | — | — | — | — | — | 1 | |
| Scheduling of the time of pembrolizumab infusions | — | — | — | — | — | 1 | |
| Bortezomib | — | — | — | — | — | 1 | |
| Mesalamine | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Tremelimumab | — | — | — | — | — | 1 | |
| Propranolol | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Loratadine | — | — | — | — | — | 1 | |
| Hydroxychloroquine | — | — | — | — | — | 1 | |
| Estradiol | — | — | — | — | — | 1 | |
| Tamoxifen | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| Carboplatin and Taxol | — | — | — | — | — | 1 | |
| Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | 4 | |||
| Dasatinib | — | — | — | — | 2 | ||
| GCAR1 | — | — | — | — | — | 2 | |
| Afatinib | — | — | — | — | — | 1 | |
| Palbociclib | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 |
Next readouts
- 2018-07-30
- 2025-11-01
- 2026-07
- 2026-08
- 2026-10-01
- 2026-12
- 2026-12
- 2026-12
- 2026-12-01
- 2026-12-30
Top conditions
- Prostate Cancer17
- Breast Cancer13
- Head and Neck Cancer7
- Cancer6
- Colorectal Cancer5
- Breast Neoplasms5
- Healthy5
- Glioma5
Frequently asked questions about AHS Cancer Control Alberta
- How many clinical trials does AHS Cancer Control Alberta have on ClinicalTrials.gov?
- AHS Cancer Control Alberta is listed as the lead sponsor on 186 clinical trials in ClinicalTrials.gov, 37 of which are currently active (recruiting, enrolling, or ongoing).
- How many of AHS Cancer Control Alberta's trials are in Phase 3?
- 9 of AHS Cancer Control Alberta's trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does AHS Cancer Control Alberta focus on?
- AHS Cancer Control Alberta's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Breast Cancer, Head and Neck Cancer, Cancer, Colorectal Cancer.
- When are AHS Cancer Control Alberta's next clinical trial readouts?
- AHS Cancer Control Alberta has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers”, expected around 2018-07-30.